Table 1 depicts the ongoing trials on different immunotherapeutic targets in NB using novel combination therapies. NCT05754684 is a phase 2 study to check the safety and efficacy of quadruple immunotherapy with NK cells, IL-2, GM-CSF, and retinoid X receptor gamma (RXRg) with inclusion criteria of creatinine clearance of ≥40 mL/min/1.73 m2. This evidence concerns the gene IL2 and neuroblastoma.